P. Freda

发表

Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults.

S. Heymsfield, S. Heshka, D. Gallagher, 2004, Journal of applied physiology.

Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study

A. Colao, L. Naves, P. Freda, 2014, Pituitary.

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

M. Fleseriu, M. Gadelha, A. Colao, 2014, The Journal of clinical endocrinology and metabolism.

Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.

D. Rabinowitz, A. J. van der Lely, P. Freda, 2005, The Journal of clinical endocrinology and metabolism.

Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission

W. Chung, J. Bruce, Yuanjia Wang, 2007, Pituitary.

Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.

A. J. van der Lely, P. Freda, M. Gordon, 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

J. A. Scarlett, L. Phillips, M. Vance, 2000, The New England journal of medicine.

Somatostatin analogs in acromegaly.

P. Freda, 2002, The Journal of clinical endocrinology and metabolism.

How effective are current therapies for acromegaly?

P. Freda, 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Spectrum of Adrenal Dysfunction in Patients with Acquired Immunodeficiency Syndrome Evaluation of Adrenal and Pituitary Reserve with ACTH and Corticotropin-Releasing Hormone Testing

R. Goland, S. Wardlaw, P. Freda, 1997, Trends in Endocrinology & Metabolism.

Long-term treatment of prolactin-secreting macroadenomas with pergolide.

A. Khandji, J. Bruce, S. Wardlaw, 2000, The Journal of clinical endocrinology and metabolism.

Pegvisomant therapy for acromegaly

P. Freda, 2006, Expert review of endocrinology & metabolism.

Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.

K. Chihara, S. Melmed, A. Klibanski, 2003, The Journal of clinical endocrinology and metabolism.

Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.

S. Wardlaw, P. Freda, K. Post, 1998, The Journal of clinical endocrinology and metabolism.

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

P. Freda, L. Anthony, 2009, Current medical research and opinion.

Surgery: Risks of pituitary surgery in the elderly

J. Bruce, P. Freda, 2010, Nature Reviews Endocrinology.

Acromegaly: Medical Management

P. Freda, 2008 .

The current status of IGF-I assays--a 2009 update.

J. Frystyk, D. Clemmons, P. Freda, 2010, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly

Zhezhen Jin, J. Bruce, W. Shen, 2021, Journal of the Endocrine Society.

Prognostic value of nadir GH levels for long-term biochemical remission or recurrence in surgically treated acromegaly

A. Khandji, S. Cremers, Zhezhen Jin, 2020, Pituitary.

Clinical utility of plasma POMC and AgRP measurements in the differential diagnosis of ACTH-dependent Cushing's syndrome.

A. Khandji, J. Bruce, S. Wardlaw, 2014, The Journal of clinical endocrinology and metabolism.

Selective use of bilateral inferior petrosal sinus sampling in patients with adrenocorticotropin-dependent Cushing's syndrome prior to transsphenoidal surgery.

P. Freda, K. Post, Jane Walsh, 2008, The Journal of clinical endocrinology and metabolism.

Leptin resistance after heart transplantation

L. Lund, D. Mancini, T. LeJemtel, 2010, European journal of heart failure.

Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women.

J. Puder, R. Goland, S. Wardlaw, 2001, The Journal of clinical endocrinology and metabolism.

IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition

Zhezhen Jin, J. Bruce, W. Shen, 2015, Pituitary.

A prospective study of appetite and food craving in 30 patients with Cushing’s disease

J. Bederson, E. Bagiella, P. Freda, 2016, Pituitary.

Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.

D. Gallagher, Zhezhen Jin, J. Bruce, 2015, The Journal of clinical endocrinology and metabolism.

Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation

L. Lund, D. Mancini, T. LeJemtel, 2009, European journal of heart failure.

Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.

J. Bruce, P. Freda, K. Post, 2014, The Journal of clinical endocrinology and metabolism.

Gender and Age in the Biochemical Assessment of Cure of Acromegaly

P. Freda, K. Post, R. Landman, 2001, Pituitary.

Differential diagnosis of sellar masses.

P. Freda, K. Post, 1999, Endocrinology and metabolism clinics of North America.

Growth hormone resistance in severe heart failure resolves after cardiac transplantation

L. Lund, D. Mancini, T. LeJemtel, 2009, European journal of heart failure.

Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI.

W. Shen, P. Freda, K. Post, 2012, The Journal of clinical endocrinology and metabolism.

Measurement of human growth hormone by immunoassays: current status, unsolved problems and clinical consequences.

M. Bidlingmaier, P. Freda, 2010, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

MRI assessment of lean and adipose tissue distribution in female patients with Cushing’s disease

W. Shen, H. Looker, P. Freda, 2010, Clinical endocrinology.

Stimulation of the Hypothalamic-Pituitary-Adrenal Axis with the Opioid Antagonist Nalmefene

S. Wardlaw, P. Freda, I. Conwell, 2005, Pituitary.

Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly.

J. Puder, P. Freda, K. Post, 2005, The Journal of clinical endocrinology and metabolism.

Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.

S. Wardlaw, P. Freda, C. M. Reyes, 2003, The Journal of clinical endocrinology and metabolism.

Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.

M. Vance, A. Klibanski, D. Hayden, 2002, The Journal of clinical endocrinology and metabolism.

Acylation of ghrelin is increased in heart failure and decreases post heart transplantation

L. Lund, D. Mancini, P. Freda, 2014, Scandinavian cardiovascular journal : SCJ.

Multidisciplinary management of acromegaly: A consensus

P. Chanson, A. Mamelak, F. Casanueva, 2020, Reviews in Endocrine and Metabolic Disorders.

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

M. Fleseriu, M. Gadelha, A. Colao, 2016, BMC Endocrine Disorders.

The Value of GH and IGF-I Measurements in the Management of Acromegaly

P. Freda, 2011 .

Monitoring of acromegaly: what should be performed when GH and IGF‐1 levels are discrepant?

P. Freda, 2009, Clinical endocrinology.

Acromegaly: Diagnostic Pitfalls

P. Freda, 2004 .

Basal and Glucose-Suppressed GH Levels Less Than 1 μg/L in Newly Diagnosed Acromegaly

J. Bruce, P. Freda, C. M. Reyes, 2004, Pituitary.

Pitfalls in the Biochemical Assessment of Acromegaly

P. Freda, 2004, Pituitary.

Current concepts in the biochemical assessment of the patient with acromegaly.

P. Freda, 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

State-of-the-art strategies for the diagnosis and management of acromegaly

S. Melmed, A. Klibanski, D. Clemmons, 2001 .

The acromegaly lipodystrophy

P. Freda, 2022, Frontiers in Endocrinology.

Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor

J. Bruce, R. Fine, P. Freda, 2011, Pituitary.

Plasma Agouti-Related Protein (AgRP) Levels in Acromegaly and Effects of Surgical or Pegvisomant Therapy.

Zhezhen Jin, J. Bruce, Sunil K. Panigrahi, 2019, The Journal of clinical endocrinology and metabolism.

Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series.

S. Wardlaw, P. Freda, K. Post, 1996, The Journal of clinical endocrinology and metabolism.

Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.

P. Freda, C. M. Reyes, S. Jehle, 2005, The Journal of clinical endocrinology and metabolism.

Diagnosis and Treatment of Pituitary Tumors

S. Wardlaw, P. Freda, 1999 .

Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure.

S. Wardlaw, P. Freda, K. Post, 2000, The Journal of clinical endocrinology and metabolism.

Primary medical therapy for acromegaly.

S. Wardlaw, P. Freda, 1998, The Journal of clinical endocrinology and metabolism.

Effects of a growth hormone receptor antagonist on bone markers in acromegaly

A. Klibanski, P. Freda, D. Kleinberg, 2002, Clinical endocrinology.

Differential Diagnosis in Cushing Syndrome: Use of Corticotropin‐Releasing Hormone

J. Bruce, R. Goland, S. Wardlaw, 1995, Medicine.

Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.

P. Freda, K. Post, C. M. Reyes, 2004, The Journal of clinical endocrinology and metabolism.

Effect of chronic opioid antagonism on the hypothalamic-pituitary-ovarian axis in hyperprolactinemic women.

M. Ferin, S. Wardlaw, P. Freda, 1995, The Journal of clinical endocrinology and metabolism.

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

Y. Wang, A. Tabarin, J. Bertherat, 2009, The Journal of clinical endocrinology and metabolism.

Hypothalamic-pituitary sarcoidosis

S. Silverberg, S. Wardlaw, P. Freda, 1992, Trends in Endocrinology & Metabolism.

A Pituitary Society update to acromegaly management guidelines

S. Samson, S. Melmed, M. Fleseriu, 2020, Pituitary.

Pituitary lymphoma presenting as fever of unknown origin.

A. Khandji, J. Bruce, S. Wardlaw, 2001, The Journal of clinical endocrinology and metabolism.

Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline

V. Montori, M. Vance, M. Molitch, 2011, The Journal of clinical endocrinology and metabolism.

Postoperative assessment of the patient after transsphenoidal pituitary surgery

J. Bruce, P. Freda, J. Ausiello, 2008, Pituitary.

Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist

J. A. Scarlett, R. K. Hutson, M. Vance, 2001, The Lancet.

Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement

P. Chanson, A. Mamelak, R. Fahlbusch, 2017, Pituitary.

Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors

Julian R. E. Davis, H. Randeva, R. Eeles, 2020, The Journal of clinical endocrinology and metabolism.

Cabergoline Therapy of Growth Hormone & Growth Hormone/Prolactin Secreting Pituitary Tumors

A. Khandji, P. Freda, K. Post, 2004, Pituitary.

Tuberculosis of the Pituitary and Sellar Region

P. Freda, 2004, Pituitary.

Simultaneous above and below approach to giant pituitary adenomas: surgical strategies and long-term follow-up

J. Bruce, Sharon Wardlaw, P. Freda, 2009, Pituitary.

Clinical review 110: Diagnosis and treatment of pituitary tumors.

S. Wardlaw, P. Freda, 1999, The Journal of clinical endocrinology and metabolism.

Sarcoidosis within a Pituitary Adenoma

A. Khandji, J. Bruce, M. Rubin, 2001, Pituitary.

OUTCOME OF IMPLEMENTATION OF A MULTIDISCIPLINARY TEAM APPROACH TO THE CARE OF PATIENTS AFTER TRANSSPHENOIDAL SURGERY.

J. Bruce, P. Freda, L. Good, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Presenting Features in 269 Patients With Clinically Nonfunctioning Pituitary Adenomas Enrolled in a Prospective Study

A. Khandji, Zhezhen Jin, J. Bruce, 2020, Journal of the Endocrine Society.

The Hormone Foundation's Patient guide to pituitary incidentaloma assessment and treatment.

M. Molitch, P. Freda, L. Katznelson, 2011, Journal of Clinical Endocrinology and Metabolism.

Primary adrenal insufficiency in patients with the acquired immunodeficiency syndrome: a report of five cases.

R. Goland, S. Wardlaw, P. Freda, 1994, Journal of Clinical Endocrinology and Metabolism.

Gonadotroph tumours with a low SF‐1 labelling index are more likely to recur and are associated with enrichment of the PI3K‐AKT pathway

A. Khandji, J. Bruce, R. Hickman, 2020, Neuropathology and applied neurobiology.

Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly.

S. Wardlaw, P. Freda, K. Post, 1998, Journal of neurosurgery.

Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under‐recognized and under‐diagnosed

Jeffrey N Bruce, J. Bruce, P. Freda, 2010, Clinical endocrinology.

Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study

M. Fleseriu, M. Gadelha, A. Colao, 2012 .

Advances in the Diagnosis of Acromegaly

P. Freda, 2000 .

Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon x-ray absorptiometry.

S. Heymsfield, D. Gallagher, W. Shen, 2009, The Journal of clinical endocrinology and metabolism.

Pasireotide LAR vs octreotide LAR in patients with acromegaly: double-blind, crossover, extension period to a randomized, double-blind, multicenter, phase III study

M. Fleseriu, M. Gadelha, A. Colao, 2012 .

Long-term Outcome of Body Composition, Ectopic Lipid, and Insulin Resistance Changes With Surgical Treatment of Acromegaly

Zhezhen Jin, J. Bruce, W. Shen, 2023, Journal of the Endocrine Society.

Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly.

S. Heymsfield, D. Gallagher, J. Bruce, 2008, The Journal of clinical endocrinology and metabolism.

Endotoxin stimulates leptin in the human and nonhuman primate.

J. Puder, M. Ferin, S. Wardlaw, 2003, The Journal of clinical endocrinology and metabolism.

What is the relationship between cardiac and peripheral ghrelin production? Reply

L. Lund, D. Mancini, P. Freda, 2009 .

Switching Patients with Acromegaly from Octreotide LAR to Pasireotide LAR Improves Biochemical Control: Crossover Extension to a Randomized, Double-Blind, Multicenter, Phase III Study

M. Fleseriu, M. Gadelha, A. Colao, 2013 .

Patient Guide to Pituitary Incidentaloma Assessment and Treatment

M. Molitch, P. Freda, L. Katznelson, 2011 .

Stimulatory effects of stress on gonadotropin secretion in estrogen-treated women.

J. Puder, R. Goland, M. Ferin, 2000, The Journal of clinical endocrinology and metabolism.

ENDOCRINEROUNDS Hypothalamic-Pituitary Sarcoidosis

S. Silverberg, S. Wardlaw, P. Freda, 1992 .

Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

S. Melmed, M. Gadelha, L. Nachtigall, 2023, Pituitary.

A. Colao, L. Naves, P. Freda, 2014, Pituitary.

Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under‐recognized and under‐diagnosed

J. Bruce, W. Ludlam, P. Freda, 2010, Clinical endocrinology.

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

M. Fleseriu, M. Gadelha, A. Colao, 2014, The Journal of clinical endocrinology and metabolism.

Differences between bone health parameters in adults with acromegaly and growth hormone deficiency: a systematic review

P. Freda, 2023, Best Practice & Research Clinical Endocrinology & Metabolism.

Persistent Deficits in Bone Quality in Treated Acromegaly: Evidence From Assessments of Microstructure

T. Nickolas, E. Stein, A. Cohen, 2023, Journal of the Endocrine Society.

MRI assessment of lean and adipose tissue distribution in female patients with Cushing’s disease

W. Shen, H. Looker, P. Freda, 2010, Clinical endocrinology.

Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.

J. Lo, S. Wardlaw, P. Freda, 2003, Obesity research.